{"log_id": 5061805106882246718, "direction": 0, "words_result_num": 26, "words_result": [{"probability": {"variance": 0.00043, "average": 0.992603, "min": 0.904775}, "location": {"width": 845, "top": 222, "height": 49, "left": 178}, "words": "血事件(包括脑出血、咯血、血尿、下消化道出血和黑便)。接受阿昔替尼治疗的1359"}, {"probability": {"variance": 0.000523, "average": 0.989196, "min": 0.887499}, "location": {"width": 813, "top": 279, "height": 47, "left": 189}, "words": "(<1%)例患者(胃出血)和接受索拉非尼治疗的3/355(1%)例患者报告致死性出血"}, {"probability": {"variance": 1.4e-05, "average": 0.998001, "min": 0.982491}, "location": {"width": 800, "top": 332, "height": 51, "left": 224}, "words": "目前尚未在未经治疗的脑转移患者或近期内出现活动性胃肠道出血患者中研究阿"}, {"probability": {"variance": 5e-05, "average": 0.997539, "min": 0.957133}, "location": {"width": 845, "top": 388, "height": 48, "left": 179}, "words": "昔替尼,不应在这些患者中使用阿昔替尼。如果出血事件需要药物干预,应暂停阿昔替"}, {"probability": {"variance": 4e-05, "average": 0.995144, "min": 0.986191}, "location": {"width": 71, "top": 461, "height": 27, "left": 180}, "words": "尼给药"}, {"probability": {"variance": 0.018985, "average": 0.918665, "min": 0.680036}, "location": {"width": 93, "top": 514, "height": 28, "left": 181}, "words": "心力表竭"}, {"probability": {"variance": 0.000427, "average": 0.992139, "min": 0.877947}, "location": {"width": 802, "top": 550, "height": 49, "left": 226}, "words": "在一项阿昔替尼治疗RCC患者的对照临床研究中,6/359例(2%)接受阿昔替尼"}, {"probability": {"variance": 0.01187, "average": 0.967594, "min": 0.433001}, "location": {"width": 837, "top": 604, "height": 51, "left": 182}, "words": "治疗的患者和3355例接受索拉非尼治疗的患者(1%)报告心力衰竭。2359例(1%"}, {"probability": {"variance": 0.000981, "average": 0.989538, "min": 0.809736}, "location": {"width": 848, "top": 658, "height": 52, "left": 182}, "words": "接受阿昔替尼治疗的患者和1355(<1%)例接受索拉非尼治疗的患者报告314级心力"}, {"probability": {"variance": 0.003634, "average": 0.980176, "min": 0.694161}, "location": {"width": 846, "top": 713, "height": 51, "left": 184}, "words": "衰竭。2359例(1%)接受阿昔替尼治疗的患者和1/355例(<1%)接受索拉非尼治疗"}, {"probability": {"variance": 1e-06, "average": 0.999178, "min": 0.996318}, "location": {"width": 276, "top": 782, "height": 36, "left": 184}, "words": "的患者报告致死性心力衰竭"}, {"probability": {"variance": 0.00193, "average": 0.9915, "min": 0.731807}, "location": {"width": 802, "top": 823, "height": 47, "left": 230}, "words": "在整个阿昔替尼治疗过程中需监测心力衰竭的体征或症状。可能需要通过永久停用"}, {"probability": {"variance": 2e-06, "average": 0.9988, "min": 0.995825}, "location": {"width": 231, "top": 892, "height": 35, "left": 185}, "words": "阿昔替尼控制心力衰竭"}, {"probability": {"variance": 0.03495, "average": 0.926852, "min": 0.398662}, "location": {"width": 209, "top": 948, "height": 32, "left": 188}, "words": "胃肠穿孔和管形成"}, {"probability": {"variance": 0.04495, "average": 0.604285, "min": 0.392271}, "location": {"width": 153, "top": 911, "height": 70, "left": 913}, "words": "不"}, {"probability": {"variance": 0.004917, "average": 0.984006, "min": 0.563705}, "location": {"width": 801, "top": 987, "height": 47, "left": 233}, "words": "在接受阿昔替尼治疗的RCC患者对照临床研究中,接受阿昔替尼治疗的1/359例"}, {"probability": {"variance": 0.0002, "average": 0.993917, "min": 0.922367}, "location": {"width": 847, "top": 1040, "height": 51, "left": 189}, "words": "患者(<1%)报告胃肠穿孔,接受索拉非尼治疗的患者未报告胃肠穿孔。在阿昔替尼临"}, {"probability": {"variance": 0.005423, "average": 0.972155, "min": 0.581461}, "location": {"width": 826, "top": 1095, "height": 50, "left": 189}, "words": "床试验中,5/715例患者(1%)报告胃肠穿孔,包括1例患者死亡。除胃肠穿孔患者外"}, {"probability": {"variance": 0.001253, "average": 0.981305, "min": 0.88985}, "location": {"width": 390, "top": 1160, "height": 40, "left": 190}, "words": "还有4/715例患者(1%)报告形成瘘管"}, {"probability": {"variance": 1.8e-05, "average": 0.997965, "min": 0.978639}, "location": {"width": 611, "top": 1209, "height": 44, "left": 237}, "words": "在阿昔替尼治疗期间,应定期监测胃肠穿孔或瘘管形成的症状"}, {"probability": {"variance": 0.00015, "average": 0.994697, "min": 0.964729}, "location": {"width": 161, "top": 1278, "height": 29, "left": 194}, "words": "甲状腺功能不全"}, {"probability": {"variance": 0.000142, "average": 0.994707, "min": 0.941972}, "location": {"width": 801, "top": 1315, "height": 50, "left": 238}, "words": "在接受阿昔替尼治疗的RCC患者对照临床研究中,接受阿昔替尼治疗的69359例"}, {"probability": {"variance": 0.003142, "average": 0.986558, "min": 0.642147}, "location": {"width": 849, "top": 1369, "height": 53, "left": 194}, "words": "患者(19%)和接受索拉非尼治疗的29/355例患者(8%)报告甲状腺功能减退。接受"}, {"probability": {"variance": 0.000777, "average": 0.990974, "min": 0.835}, "location": {"width": 847, "top": 1425, "height": 52, "left": 195}, "words": "阿昔替尼治疗的4/359例患者(1%)和接受索拉非尼治疗的4/355例患者(1%)报告"}, {"probability": {"variance": 0.000236, "average": 0.992694, "min": 0.949699}, "location": {"width": 137, "top": 1581, "height": 24, "left": 555}, "words": "第10页,共27页"}, {"probability": {"variance": 0.000414, "average": 0.984579, "min": 0.931368}, "location": {"width": 66, "top": 1614, "height": 20, "left": 287}, "words": "20150429"}], "language": 3}